AXSM · Axsome Therapeutics Inc
Price
Snapshot
50 fields · last close| Market Cap | $10.91B |
| P/E | — |
| Float | 43.19M |
| Beta | 0.81 |
| Volatility | 20.3% |
| Exchange | NASDAQ |
| Sector | Pharmaceuticals |
| Cap tier | Large cap |
| Macro sensitivity | Moderate |
| Clavix score | 72 |
| Price | 206.85 |
| Change | −0.72% |
| Prev Close | 208.35 |
| Open | 209.32 |
| Day Low | 206.60 |
| Day High | 210.59 |
| Avg Vol | 1 |
| Avg $ Vol | $115.7M |
| 52W High | 260.19 |
| 52W Low | 112.90 |
| 52W Pos | 63.8% |
| From High | −20.50% |
| From Low | +83.22% |
| Max DD 1Y | −22.20% |
| Spread | 0.10% |
| Liquidity | Normal |
| SMA 20 | −1.51% |
| SMA 50 | −7.81% |
| SMA 200 | +6.39% |
| RSI (14) | 44.9 |
| Vol 30D | 37.5% |
| Vol 90D | 43.4% |
| 1Y Range | 113–260 |
| Daily bars | 889 |
| Perf Week | +1.01% |
| Perf Month | −2.11% |
| Perf Quarter | −9.99% |
| Perf Half Y | +29.04% |
| Perf Year | +70.78% |
| Perf YTD | +15.76% |
| Prev Day | −0.72% |
| Clavix | B |
| Debt / Eq | 3.25 |
| Curr Ratio | 2.11 |
| Int Cover | -37.1× |
| FCF Margin | — |
| Rev Growth | +45.5% |
| Profit | Unprofitable |
| Leverage | Very High |
| Sector rank | 9 / 15 |
Clavix risk grade
regraded every trading dayAXSM grades B, 72 of 100. Steadiest on News Sentiment (65), most exposed on Price Stability (55, mixed). 0 of the 4 weighted dimensions sit above the Pharmaceuticals median. Ranks 9 of 15 in Pharmaceuticals by Clavix score.
How rough the ride is
| AXSM | Pharmaceuticals median | |
|---|---|---|
| Betavs the overall market · lower is steadier | 0.81 | 0.43 |
| Volatilityannualized | 20.3% | 10.7% |
| Max drawdown, past yearworst peak-to-trough fall | −22.2% | — |
| Typical daily movemedian absolute daily change | 1.26% | — |
| Days beyond ±3%of the last 252 sessions | 4417% | — |
How its days are spread
Daily returns over the last 252 sessions in 1% bins. Moves beyond ±6% land in the end bins.
52-week range
The bar runs from the lowest to the highest close of the last 252 sessions; the marker is the latest close.
Drawdown from the 1-year peak
Percent below the running high over the last 12 months. Zero is a fresh high.
Market sensitivity
| AXSM | Pharmaceuticals median | |
|---|---|---|
| Beta to the markethow much it swings with the S&P 500 · lower is safer | 0.81 | 0.43 |
| Macro sensitivityrate, dollar and credit exposure bucket | Moderate | Low67% of 15 |
Where it sits on the macro scale
Low means rates, the dollar and credit spreads barely move it. Very High means they drive a large share of its swings. The counts are how many Pharmaceuticals names sit in each bucket.
Where it ranks in its sector
Rank by Clavix score within the sector. Right is the top of the sector.
Price performance
| AXSM | |
|---|---|
| 1 week | +1.0% |
| 1 month | −2.1% |
| Year to date | +15.8% |
| 1 year | +70.8% |
Context for the rank, not itself a risk measure.
Recent coverage, scored
| AXSM | |
|---|---|
| Articles scoredthe most recent scored coverage, up to 30 | 26since 26 Jun |
| Average score0 most bearish, 100 most bullish | 58 |
| Bullish · bearisharticles above 60 · below 40 | 16 · 5 |
| Directionarticles whose tone is improving vs worsening | 16 ↑ 5 ↓ |
Where the article scores land
Each bar is a 10-point band of article scores. Below 40 reads bearish, above 60 bullish.
Balance sheet, against the sector
The shaded band is the middle half of the 15 Pharmaceuticals names Clavix covers; the tick is the sector median.
Growth
| AXSM | |
|---|---|
| Revenue growthyear over year | +45.5% |
Financial Health is shown but does not count toward the grade. Why
0–100, higher is safer. The tick on each bar is the Pharmaceuticals median. Click a dimension for the evidence behind it. Financial Health is shown but does not count toward the grade.
Against Pharmaceuticals
15 companies| Metric | AXSM | Sector spread | Median |
|---|---|---|---|
| Beta | 0.81 | 0.43 | |
| Volatility | 20.3% | 10.7% | |
| Debt / equity | 3.25 | 0.94 | |
| Current ratio | 2.11 | 1.86 | |
| Interest coverage | -37.1× | 5.9× |
Recent news
most recent scored articles · the chip is the article’s score · click to openAxsome has started giving patients its drug AXS-05 in a Phase III trial called SUMMIT to see whether it helps adults quit smoking.
The Manufacturers Life Insurance Company bought a new position in Axsome Therapeutics in the second quarter, purchasing 118,999 shares worth roughly $29.1 million, according to its SEC filing.
HC Wainwright analyst R. Selvaraju lowered his Q4 2027 earnings-per-share estimate for Axsome Therapeutics, according to a research note issued Monday, August 24th. The article body is truncated, so the specific revised figures are not available.
Axsome Therapeutics stock is up 16% year to date. The company is expanding its approved portfolio and has a deep pipeline of products that could launch soon, and Wall Street thinks the stock has more room to rise.
Axsome Therapeutics (AXSM) shares are up 16% so far this year, beating the S&P 500's 11% gain, and Wall Street analysts have an average price target of $285.42, suggesting about 37% more upside. The company sells four approved drugs, led by the depression drug Auvelity, and reported second-quarter revenue of $218.4 million, up 46% from a year earlier.
Nearest peers by size
Pharmaceuticals| Ticker | Company | Grade | Mkt cap | P/E | Beta | |
|---|---|---|---|---|---|---|
| CORT | Corcept Therapeutics Inc | C- | $12.19B | 216.52 | 0.50 | Compare |
| ELAN | Elanco Animal Health Inc | B- | $12.20B | — | 1.75 | Compare |
| CRNX | Crinetics Pharmaceuticals Inc | D+ | $9.01B | — | 0.45 | Compare |
| JAZZ | Jazz Pharmaceuticals PLC | A- | $16.07B | 17.04 | 0.38 | Compare |
| VTRS | Viatris Inc | B+ | $20.71B | — | 0.91 | Compare |
| MANE | Veradermics Inc | D- | $4.08B | — | -0.14 | Compare |
| ZTS | Zoetis Inc | B | $31.87B | 12.03 | 0.69 | Compare |
| RPRX | Royalty Pharma PLC | A | $36.73B | 45.07 | 0.38 | Compare |
You just read one holding. Clavix reads the whole portfolio.
Every position you own, graded on the same five dimensions, with an alert when a grade moves. Three months free on iPhone.